Homology Medicines, Inc. (FIXX)

2.8900 +0.1300 (+4.71%) At close: 04:00PM EDT

Homology Medicines, Inc.

One Patriots Park
Bedford, MA 01730
United States
781 301 7277
https://www.homologymedicines.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 224

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Arthur O. Tzianabos Ph.D.	CEO & Director	912.5k	N/A	1963
Dr. Albert Seymour Ph.D.	Pres & Chief Scientific Officer	638.7k	N/A	1968
Mr. W. Bradford Smith CPA, M.B.A.	CFO, Treasurer & Chief Bus. Officer	755.8k	N/A	1956
Dr. Saswati Chatterjee Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Julie Jordan M.D.	Sr. VP and Head of Clinical Devel. & Operations	N/A	N/A	N/A
Dr. Paul Alloway J.D., Ph.D.	Chief Legal Officer & Sec.	N/A	N/A	1971
Ms. Theresa McNeely	Chief Communications Officer & Patient Advocate	N/A	N/A	1964
Ms. Melissa Gelormini	VP of HR	N/A	N/A	N/A
Mr. Michael Blum M.B.A.	Chief Commercial Officer	N/A	N/A	1968
Dr. Deborah Kinch Ph.D.	Chief Devel. Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Corporate Governance

Homology Medicines, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.